PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A. (PHXM) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001624422 · PHXM · NASDAQ · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001624422 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
No recent filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) has submitted 189 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2017. As a Healthcare sector company with CIK 0001624422, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is PHAXIAM Therapeutics S.A.'s most comprehensive regulatory disclosure. The most recent PHAXIAM Therapeutics S.A. 10-K was filed on 2023-03-28 for fiscal year ending 2023. Historical PHXM 10-K annual reports are available from 2014 through 2023.
Investors researching PHAXIAM Therapeutics S.A. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
PHXM SEC Filings · 8 questionsPHAXIAM Therapeutics S.A. (PHXM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 189 filings and access original documents at no cost. PHAXIAM Therapeutics S.A.'s CIK is 0001624422.